Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Benazepril · 2 trials · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| 2 | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Benazepril HCl 40 mg Tablets | DRUG | 1 x 40 mg, single-dose fed |
| Lotensin® 40 mg Tablets | DRUG | 1 x 40 mg, single-dose fed |
Inclusion Criteria: * Screening Demographics: All volunteers for selected for this study will be healthy men or women 19 years of age or older at the time of dosing. The weight range will not exceed ±20% for height and body frame as per Desirable Weights for Men - 1983 Metropolitan height and Weigh...
Benazepril is an investigational small molecule being studied in healthy volunteers. It is currently in Phase 1 clinical development, with trials evaluating the drug in healthy adult participants. The specific medical condition it is intended to treat has not been established, as the current studies focus on healthy individuals.
Benazepril is being developed by Teva Pharmaceutical Industries Limited, which trades under the ticker TEVA. The company is conducting Phase 1 clinical trials to evaluate the drug's effects in healthy volunteers.
Benazepril is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still undergoing clinical trials to assess its safety and pharmacokinetics in healthy participants.
Benazepril has two completed Phase 1 clinical trials: NCT00836537, which evaluated the drug under fed conditions, and NCT00836576, which evaluated it under fasting conditions. Both trials enrolled 40 healthy adults each in the United States, with a total enrollment of 80 participants.
Benazepril is the active ingredient in the drug product benazepril hydrochloride. The clinical trials for this asset are titled "Benazepril HCl 40 mg Tablets," indicating that the drug is formulated as the hydrochloride salt of benazepril.